학술논문

Effect of Immune-Modulatory Interventions on Asymptomatic Cytomegalovirus Shedding During Suppressive Antiretroviral Therapy
Document Type
article
Source
The Journal of Infectious Diseases. 228(1)
Subject
Medical Microbiology
Biomedical and Clinical Sciences
Immunology
Clinical Research
Infectious Diseases
HIV/AIDS
Prevention
Sexually Transmitted Infections
Clinical Trials and Supportive Activities
2.1 Biological and endogenous factors
Evaluation of treatments and therapeutic interventions
6.1 Pharmaceuticals
Aetiology
Infection
Good Health and Well Being
Male
Humans
Female
Cytomegalovirus
Cytomegalovirus Infections
DNA
Viral
HIV Infections
HIV
Inflammation
Virus Shedding
CMV
immune modulators
ruxolitinib
sirolimus
Biological Sciences
Medical and Health Sciences
Microbiology
Biological sciences
Biomedical and clinical sciences
Health sciences
Language
Abstract
Long-term consequences of human immunodeficiency virus (HIV) are likely the result of persistent inflammation and immune dysfunction of which cytomegalovirus (CMV) is a known contributor. We leveraged 2 AIDS Clinical Trials Group clinical trials exploring the effects of immune modulators (ruxolitinib and sirolimus) on inflammation in people with HIV on antiretroviral therapy to determine whether these interventions affected CMV shedding at various mucosal sites. Analyzing 635 mucosal samples collected, we found no significant difference in CMV levels across study arms or time points. Men had more CMV shedding than women. We did confirm an association between higher CMV DNA and immune markers associated with HIV persistence and HIV-associated mortality rates.